hackint0sh/New-Dataset huggingface dataset:
A total of 120 participants will be enrolled, participants will be randomized 1:1 to receive a single dose of Recombinant COVID-19 vaccine (Sf9 Cell) (test group) or COVID-19 Vaccine (Vero Cell), Inactivated. conditions: COVID-19 conditions: SARS-CoV-2 Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 120 type: ACTUAL name: Recombinant COVID-19 Vaccine (Sf9 Cell) name: COVID-19 Vaccine (Vero Cell), Inactivated measure: Incidence of adverse drug reactions (ADRs) measure: Geometric mean titer (GMT) of specific neutralizing antibody against SARS-CoV-2 prototype strain measure: Geometric mean titer (GMT) of specific neutralizing antibody against SARS-CoV-2 Omicron variant measure: Geometric mean increase (GMI) of specific neutralizing antibody against SARS-CoV-2 prototype strain measure: Geometric mean increase (GMI) of specific neutralizing antibody against SARS-CoV-2 Omicron variant measure: GMT and GMI of specific neutralizing antibody against SARS-CoV-2 prototype strain measure: GMT and GMI of specific neutralizing antibody against SARS-CoV-2 omicron variant measure: GMT and GMI of IgG antibodies against SARS-CoV-2 S protein RBD sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: West China Hospital of Sichuan University city: Chengdu state: Sichuan country: China lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06381830 id: ASCT+CART briefTitle: Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma overallStatus: RECRUITING date: 2024-01-01 date: 2027-01-01 date: 2027-01-01 date: 2024-04-24 date: 2024-04-24 name: The First Affiliated Hospital of Soochow University class: OTHER name: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd name: Suzhou Hongci Hematology Hospital, Suzhou, China briefSummary: The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma. conditions: Lymphoma, B-Cell conditions: Autologous Stem Cell Transplantation studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Apheresis name: Autologous Stem Cell Transplantation name: CAR-T Cell Therapy measure: Overall Response Rate (ORR) measure: Progression-free Survival（PFS） measure: Duration of Response(DOR) measure: Complete Response Rate measure: Overall Survival（OS） measure: Adverse events profile sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Soochow University status: RECRUITING city: Suzhou state: Jiangsu zip: 215000 country: China name: Caixia Li, M.D. role: CONTACT phone: +86 512 67781856 email: licaixia@suda.edu.cn lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06381817 id: 2024112 briefTitle: Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients overallStatus: RECRUITING date: 2024-04-01 date: 2028-03-31 date: 2028-03-31 date: 2024-04-24 date: 2024-04-26 name: The First Affiliated Hospital of Soochow University class: OTHER name: Children's Hospital of Soochow University name: Ruijin Hospital name: Nanfang Hospital, Southern Medical University name: Fujian Medical University Union Hospital name: First Affiliated Hospital Xi'an Jiaotong University name: Wuhan Union Hospital, China name: Zhejiang University briefSummary: The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:
Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion. conditions: Acute T Cell Lymphoblastic Leukemia conditions: Haploidentical Hematopoietic Stem Cell Transplantation conditions: Cord Blood studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 146 type: ESTIMATED name: Haplo-cord HCT name: Haplo-HCT measure: Progression-free survival measure: Overall survival measure: Cumulative incidence of relapse measure: Non-relapse mortality measure: Adverse events sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Soochow University status: RECRUITING city: Suzhou state: Jiangsu zip: 215000 country: China name: Yang XU role: CONTACT phone: 86+051267781850 email: xuyang1020@126.com name: Yang Xu role: PRINCIPAL_INVESTIGATOR lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06381804 id: 24YL9001 briefTitle: Effect of Shotblocker and Palm Stimulator overallStatus: RECRUITING date: 2024-04-19 date: 2024-05 date: 2024-05 date: 2024-04-24 date: 2024-04-24 name: Necmettin Erbakan University class: OTHER briefSummary: This study discusses the advancements in nursing, particularly focusing on intramuscular injections, their complications, and innovative non-pharmacological methods such as the Shotblocker and palm stimulator to reduce pain. These methods, based on the gate control theory, aim to minimize discomfort during injections by applying tactile stimulation, which has proven effective in various studies. conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 96 type: ESTIMATED name: shotblocker name: palm stimulator measure: Visual analog scale (VAS) pain Scale score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Necmettin Erbakan University status: RECRUITING city: Meram country: Turkey name: Gülden Basit role: CONTACT phone: (0 332) 320 40 29 email: guldenbasit@gmail.com role: CONTACT phone: (0 332) 320 40 29 name: Merve Öz role: SUB_INVESTIGATOR lat: 37.82985 lon: 32.46777 hasResults: False
nctId: NCT06381791 id: PRO00036811 briefTitle: CBD for Pain Following Orthopedic Shoulder Surgery acronym: CBD overallStatus: RECRUITING date: 2024-05-01 date: 2026-12-30 date: 2027-12-30 date: 2024-04-24 date: 2024-04-24 name: The Methodist Hospital Research Institute class: OTHER briefSummary: The goal of the study is to learn if Epidiolex (cannabidiol) works as a additional pain medication in patients who have had orthopedic shoulder surgery. It is also to learn about safe dosages and identify any side effects after surgery.
* Have bloodwork tested after surgery conditions: Shoulder Osteoarthritis conditions: Rotator Cuff Injuries studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is designed as a randomized, double-blinded controlled trial. Patients will be recruited in clinic preoperatively prior to their scheduled procedure. Patients and the treating physician/research study team will be blinded to the treatment arm. Patients will be randomized to either the test group, which will be prescribed Epidiolex (cannabidiol) postoperatively in addition to the standard pain regimen, or the control group, which will have a placebo provided in addition to the standard pain regimen. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 80 type: ESTIMATED name: Epidiolex name: Placebo oral solution measure: Primary - Pain Journal measure: Survey Data measure: Pain Disability Index (PDI) measure: Pain, Enjoyment, General Activity (PEG) Scale measure: Patient Health Questionnaire 4 (PHQ-4): The four-item patient health questionnaire for anxiety measure: Pittsburgh Sleep Quality Index (PSQI) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Houston Methodist Hospital status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: Haley M Goble, MHA, CRCC role: CONTACT phone: 713-441-3930 email: hmgoble@houstonmethodist.org name: Patrick C McCulloch, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06381778 id: 112006-E briefTitle: Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis overallStatus: RECRUITING date: 2023-02-06 date: 2027-12-01 date: 2027-12-01 date: 2024-04-24 date: 2024-04-24 name: Far Eastern Memorial Hospital class: OTHER briefSummary: Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific "red-flag" signs of Fabry disease in Taiwan. conditions: Hypertrophic Cardiomyopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 2600 type: ESTIMATED measure: Death measure: CV death sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Far Eastern Memorial Hospital status: RECRUITING city: New Taipei City zip: 220 country: Taiwan name: Yen-Wen Wu, MD, PhD role: CONTACT phone: 886-2-8966-7000 phoneExt: 1090 email: wuyw0502@gmail.com name: Yen-Wen Wu, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 25.01111 lon: 121.44583 hasResults: False
nctId: NCT06381765 id: Serratus-Pectointercostal briefTitle: Serratus Plane Block and Pectointercostal Block overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2024-08-01 date: 2024-04-24 date: 2024-04-24 name: Cukurova University class: OTHER briefSummary: ASA I-II female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. Patients will divide into 2 groups. Deep serratus plane block will perform with 0,25 %bupivacaine 20 ml at the midaxillary 5. rib, bilaterally for Group I. At Group II, deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally . General anesthesia with sevoflurane and remifentanil will perform to the all patients. Postoperative pain scores, morphine consumption and complications will record till the 24.th hours. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Serratus plane bock and pectointercostal block measure: postoperative morphine consumption measure: postoperative visual analog scale scores sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06381752 id: CPMvsPT briefTitle: Value of Continuous Passive Motion in Rehabilitation After Total Knee Replacement overallStatus: COMPLETED date: 2019-06-25 date: 2020-03-31 date: 2020-03-31 date: 2024-04-24 date: 2024-04-24 name: Johannes Gutenberg University Mainz class: OTHER briefSummary: Immediate rehabilitation after total knee arthroplasty (TKA) differs in terms of volume, intensity but also type of treatment. Continuous passive motion after TKA is so far only investigated for replacing physiotherapy. This study is conducted to investigate CPM when it partially replaces group physiotherapy in terms of functional and patient-reported outcomes. conditions: Total Knee Arthroplasty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 175 type: ACTUAL name: Continuous passive motion name: standard rehabilitation measure: Staffelstein Score measure: Oxford Knee Score (OKS) measure: Range of motion (ROM) measure: Visual Analogue Scale (VAS) measure: Return to work sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitaetsmedizin der JGU Mainz city: Mainz state: Rheinland-Pfalz zip: 55131 country: Germany lat: 49.98419 lon: 8.2791 hasResults: False
nctId: NCT06381739 id: M011 briefTitle: A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol acronym: AeroVax overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-07 date: 2026-07 date: 2024-04-24 date: 2024-04-25 name: McMaster University class: OTHER name: Canadian Institutes of Health Research (CIHR) briefSummary: The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).
In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy). conditions: COVID-19 Infection studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 350 type: ESTIMATED name: ChAd-triCoV/Mac name: Control measure: Antigen specific T cell responses in blood. measure: Antigen specific T cell responses in bronchoalveolar lavage (BAL). measure: Any grade 3, 4, or 5 adverse events that are possibly or probably related to study vaccine. measure: Confirmed COVID infection by reverse transcriptase polymerase chain reaction (RT-PCR) measure: CD4 and CD8 T cell responses specific for the spike (S1), nucleoprotein (N) and polymerase (POL) SARS-CoV-2 antigens expressed by the vaccine, including those expressing memory T cell markers, in the peripheral blood. measure: Neutralizing and total antibody levels in BAL and blood measure: Any adverse events, including grade 1 or 2 or where relationship to vaccine/placebo administration or study procedures is judged not related or unlikely. measure: Tissue-resident memory surface marker expression airway T cells sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Health Sciences Centre city: Hamilton state: Ontario zip: L8S 4K1 country: Canada lat: 43.25011 lon: -79.84963 hasResults: False
nctId: NCT06381726 id: Progetto AIRC IG-2022 ID 27184 briefTitle: Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life overallStatus: RECRUITING date: 2024-03-07 date: 2028-02-28 date: 2028-02-28 date: 2024-04-24 date: 2024-04-24 name: University of Milan class: OTHER name: University of Turin, Italy briefSummary: Background Lower-grade-gliomas affect young patients, thus the longest progression-free-survival (PFS) with a high level quality of life is crucial. Surgery most significantly impacts on tumor natural history, postponing recurrence, improving symptoms, decreasing the need of adjuvant therapies, with extent of resection, gross-total and supra-total (GTR and STR), strongly associating with longest PFS. Achievement of GTR or STR depends on the degree of functional reorganization induced by glioma. Consequently, a successful treatment fostering neural circuit reorganization before surgery, would increase the chance of GRT/STR.
Aims The project has 4 aims, investigating: A) the presurgical functional (FC) and structural (SC) connectomics of the hand-motor network to picture the spontaneous reorganization and the influence of clinical, imaging and histomolecular variables; B) the dynamic of FC and SC after tumor resection; C) changes in FC and SC maps after personalized upfront motor rehabilitation and/or chemotherapy; D) the effect of FC and SC upfront treatment on the achievement of GTR/STR preserving hand dexterity.
Impact On Cancer Results will increase the achievement of GTR/STR, preserving motor integrity, with dramatic impact on LGGs natural history. conditions: Glioma conditions: Glioma, Malignant studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients immediately candidate for resection will be assessed neurologically, neuropsychologically and by functional MRI. Extent of resection will be assessed on \<48hrs and 2-month MRI. Neurological and neuropsychological assessment will be performed during regular follow-up. Patients not requiring an adjuvant treatment according to tumor board meeting will be submitted to functional MRI at 4-8 and 12 months from surgery. Patients not immediately eligible for resection will be submitted to biopsy for histomolecular definition. Patients not requiring radiation therapy will be submitted to neurological, neuropsychological, and functional MRI evaluation. Upon clinical context, patients will undergo motor rehabilitation and/or chemotherapy. After 3-6 months, patients will undergo functional MRI and evaluated for surgery. Neurological and neuropsychological evaluation will be performed at treatment initiation, every month during treatment, at admission for surgery and 1 month after surgery. primaryPurpose: TREATMENT masking: NONE count: 400 type: ESTIMATED name: Resting State Functional Magnetic Resonance Imaging (rs-fMRI) name: Up-front Motor Rehabilitation name: Up-front Chemotherapy measure: Muscle power measure: Motor praxia measure: Comprehensive neuropsychological assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale Galeazzi Sant'Ambrogio status: RECRUITING city: Milan state: Lombardy zip: 20157 country: Italy name: Lorenzo Bello, MD role: CONTACT phone: 0039-340-217-1453 email: lorenzo.bello@unimi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06381713 id: ONZ-2024-0158 briefTitle: Effect and Cost-utility of of High Intensity vs. Low Intensity Speech Intervention in Children With Cleft Palate overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-12 date: 2027-12 date: 2024-04-24 date: 2024-04-24 name: University Ghent class: OTHER name: Research Foundation Flanders briefSummary: Achieving speech that is understandable and acceptable to others is the key outcome in cleft treatment. Therefore, speech therapy provided by a speech-language pathologist is necessary. This intervention is traditionally provided twice per week for 30 minutes for months or even years by first-line speech-language pathologists. Unfortunately, this low intensity intervention is based on a historical context rather than scientific evidence. This means that current speech therapy knows several shortcomings including poor outcomes, treatment fatigue and high costs related to year-long therapy. Because of these issues, the use of high intensity speech intervention is proposed. Even though solid proof-of-concepts exist for this model, it has not yet found its way into clinical practice.
Before this intensity can be implemented and utilized in clinical practice, the effect of this novel program on a larger societal scale must be determined. This project will compare the effect of high intensity and low intensity speech intervention in children with a cleft palate in terms of speech, quality of life, and cost-utility as provided by first-line speech-language pathologists by conducting a large-scale randomized controlled trial. The final goal is to utilize this program in clinical practice and to create awareness of the benefits for children with a cleft palate among stakeholders. conditions: Cleft Palate Children conditions: Speech Therapy conditions: Speech Disorders in Children conditions: Cleft Lip and Palate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 70 type: ESTIMATED name: High intensive combined phonetic-phonological intervention name: Low intensive combined phonetic-phonological intervention measure: Consonant proficiency measure: Incremental cost-utility ratio measure: Incremental cost-effectiveness ratio measure: Intelligibility in Context measure: Health-related quality of life measure: Speech Function measure: Speech Distress measure: Communication attitudes of children aged 4 and 5 years measure: Communication attitudes of children aged 6 years and older sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06381700 id: DF CO2405/0014 (P) briefTitle: Effectiveness of MySmile App for Improving the Oral Health of Secondary School Children: overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-06 date: 2025-06 date: 2024-04-24 date: 2024-04-24 name: University of Malaya class: OTHER briefSummary: The goal of this cluster-randomised control trial is to assess the effectiveness of the MySmile app for improving oral health in secondary school children. The main questions it aims to answer are:
Participants in the intervention group will receive the SDS and MySmile app. The control group will receive SDS only. Therefore the researcher will compare between the intervention and control group in terms of dental plaque, gingival health, oral health knowledge, oral health attitudes and oral health behaviours. conditions: Oral Disease conditions: Gingival Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 303 type: ESTIMATED name: MySmile app name: Control measure: The mean decrement in plaque score will be assessed using the Plaque Control Record developed by O'Leary Drake and Naylor in 1972 measure: The mean increment in gingival health will be assessed using Gingival Index developed by Silness and Loe in 1963 measure: The mean increment of oral health knowledge, attitude and practice using validated questionnaires. sex: ALL minimumAge: 15 Years maximumAge: 17 Years stdAges: CHILD facility: Muhammad Hamidie bin Saari city: Kuala Lumpur state: Wilayah Persukutuan Kuala Lumpur zip: 50480 country: Malaysia name: Zamros Yuzadi Mohd Yusof, PHD role: CONTACT name: Zamros Yuzadi Mohd Yusof, PHD role: PRINCIPAL_INVESTIGATOR name: Marhazlinda Jamaludin, Master role: PRINCIPAL_INVESTIGATOR name: Unaizah Hanum Obaidellah, PHD role: PRINCIPAL_INVESTIGATOR name: Nazirah Ab Mumin, PHD role: PRINCIPAL_INVESTIGATOR lat: 3.1412 lon: 101.68653 hasResults: False
nctId: NCT06381648 id: 23228/LyMIC briefTitle: Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) acronym: LyMIC overallStatus: RECRUITING date: 2023-04-15 date: 2026-06-18 date: 2026-06-18 date: 2024-04-24 date: 2024-04-25 name: City of Hope Medical Center class: OTHER briefSummary: Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC.